Synthetic lethality: Exploiting the addiction of cancer to DNA repair

Blood

Volumn 117, Issue 23, 2011, Pages 6074-6082

  Shaheen, Montaser ^a   Allen, Christopher ^b   Nickoloff, Jac A ^b   Hromas, Robert ^c  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 6 O BENZYLGUANINE; 7 HYDROXYSTAUROSPORINE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AMUVATINIB; ANTINEOPLASTIC AGENT; AZD 7762; BORTEZOMIB; CAMPTOTHECIN; CCT 241533; CEP 8933; CHIR 124; CISPLATIN; CP 466722; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUOROURACIL; GPI 21016; INIPARIB; INO 1001; KU 7441; LOMEGUATRIB; LY 2603618; MELPHALAN; METHOTREXATE; MK 4827; OLAPARIB; OXALIPLATIN; PF 00477736; TEMOZOLOMIDE; TRC 102; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; XL 844;

ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPETITIVE INHIBITION; DISEASE EXACERBATION; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOXICITY; EXCISION REPAIR; GENE MUTATION; GENE TARGETING; GENETIC PREDISPOSITION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; HYPERGLYCEMIA; MISMATCH REPAIR; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

EID: 79959397953     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-313734     Document Type: Review

References (96)

1. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837.
2. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol. 2006; 24(23):3799-3808. (Pubitemid 46622318)
3. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749-1753.
4. McKinnon PJ, Caldecott KW. DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet. 2007;8:37-55.
5. Futreal PA, Liu Q, Shattuck-Eidens D, et al. 2 BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266(5182):120-122. (Pubitemid 24345332)
6. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792. (Pubitemid 26004412)
7. Nouspikel T. DNA repair in mammalian cell: nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66(6):994-1009.
8. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75(5):1027-1038. (Pubitemid 24014559)
9. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462(7276): 1005-1010.
10. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233-245. (Pubitemid 46480968)
11. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179-204.
12. Ward I, Kim JE, Minn K, et al. The tandem BRCT domain of 53BP1 is not required for its repair function. J Biol Chem. 2006;281(50):38472-38477. (Pubitemid 46041971)
13. Wang M, Wu W, Wu W, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170-6182. (Pubitemid 44942738)
14. Lieber MR. The mechanism of human nonnhomologous DNA end joining. J Biol Chem. 2008;283(1):1-5.
15. Mimitou EP, Symington LS. Ku prevents Exo1 and Sgs1-dependent resection of DNA ends in the absence of a functional MRX complex or Sae2. EMBO J. 2010;29(19):3358-3369.
16. Jacobs C, Huang Y, Masud T, et al. A hypomorphic Artemis human disease allele causes aberrant chromosomal rearrangements and tumorigenesis. Hum Mol Genet. 2011;20(4):806-819.
17. Hammel M, Yu Y, Mahaney BL, et al. Ku and DNA-dependent protein kinase dynamic conformations and assembly regulate DNA binding and the initial non-homologous end joining complex. J Biol Chem. 2010;285(2):1414-1423.
18. Lee SH, Oshige M, Durant S, et al. The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci U S A. 2005;102 (50):18075-18080. (Pubitemid 41798504)
19. Fnu S, Williamson EA, De Haro LP et al. Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining. Proc Natl Acad Sci U S A. 2011;108(2):540-545.
20. Chan DW, Chen BP-C, Prithivirasingh S, et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev. 2002;16(18):2333-2338. (Pubitemid 35034402)
21. Dahm K. Role and regulation of human XRCC4-like factor/cernunnos. J Cell Biochem. 2008; 104(5):1534-1540.
22. Rupnik A, Lowndes NF, Grenon M. MRN and the race to the break. Chromosoma. 2010;119(2): 115-135.
23. You Z, Shi LZ, Zhu Q, et al. CtIP links DNA double-strand break sensing to resection. Mol Cell. 2009;36(6):954-969.
24. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/ DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem. 2004;279(53):55117-55126. (Pubitemid 40066505)
25. Bothmer A, Robbiani DF, Feldhahn N, et al. 53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination. J Exp Med. 2010; 207(4):855-865.
26. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229-257.
27. Nimonkar AV, Sica RA, Kowalczykowski SC. Rad52 promotes second-end DNA capture in double-stranded break repair to form complement-stabilized joint molecules. Proc Natl Acad Sci U S A. 2009;106(9):3077-3082.
28. Weinstock DM, Richardson CA, Elliott B, Jasin M. Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair. 2006;5(9-10):1065-1074. (Pubitemid 44291619)
29. Robertson AB, Klungland A, Rognes T, et al. DNA repair in mammalian cells: Base excision repair: the long and short of it. Cell Mol Life Sci. 2009; 66(6):981-993.
30. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18:85-98.
31. Shaheen M, Shanmugam I, Hromas R. The role of PCNA post-translational modifications in translesion synthesis. J Nucleic Acids. 2010; 2010:pii:761217. doi:10.4061/2010/761217.
32. Budzowska M, Kanaar R. Mechanisms of dealing with DNA damage-induced replication problems. Cell Biochem Biophys. 2009;53(1):17-31.
33. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 2008;9(3):297-308. (Pubitemid 351430844)
34. Dobzhansky T. Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura. Genetics. 1946; 31(3):269-290.
35. Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics. 1968;59:37-44.
36. Hartwell L, Szankasi P, Roberts C, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278(5340):1064-1068. (Pubitemid 27517876)
37. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245- 251.
38. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
39. Simon JA, Szankasi P, Nguyen DK, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 2000;60(2):328-333. (Pubitemid 30070759)
40. Dunstan HM, Ludlow C, Goehle S, et al. Cellbased assays for identification of novel doublestrand break-inducing agents. J Natl Cancer Inst. 2002;94(2):88-94. (Pubitemid 34121287)
41. Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009;137(5):821-834.
42. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108- 112.
43. Kroll ES, Hyland KM, Hieter P, et al. Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics. 1996;143(1):95-102. (Pubitemid 26136975)
44. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39(1): 8-24.
45. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-917. (Pubitemid 40559005)
46. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035): 917-921. (Pubitemid 40559006)
47. Branzei D, Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol. 2010;11(3):208-219.
48. Gottipati P, Vischioni B, Schultz N, et al. Poly-(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010;70(13):5389-5398.
49. Fong PC, Boss DS, Yap TA, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
50. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
51. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triplenegative breast cancer. N Engl J Med. 2011;364: 205-214.
52. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16): 8109-8115. (Pubitemid 44299177)
53. Lord CJ, McDonald S, Swift S, et al. A highthroughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst). 2008;7(12):2010-2019.
54. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009; 1(6-7):315-322.
55. McCabe N, Cerone MA, Ohishi T, et al. Targeting Tankyrase 1 as a therapeutic strategy for BRCAassociated cancer. Oncogene. 2009;28(11):1465-1470.
56. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614.
57. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-3226.
58. Morrison A, Johnson AL, Johnston LH, et al. Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J. 1993;12:1467-1473. (Pubitemid 23112800)
59. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 2010;17(3): 235-248.
60. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med. 2009;1(6-7):323-337.
61. Jiang H, Reinhardt HC, Bartkova J. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009;23(16):1895-1909.
62. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res. 2010;16(18):4527-4531.
63. Nghiem P, Park P, Kim Y, et al. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A. 2001;98(16):9092-9097. (Pubitemid 32743874)
64. Bartz SR, Zhang Z, Burchard J, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol. 2006; 26(24):9377-9386. (Pubitemid 44904431)
65. Sur S, Pagliarini R, Bunz F, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A. 2009;106(10):3964-3969.
66. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3(5):421-9. (Pubitemid 38340288)
67. Wang Q, Fan S, Eastman A, et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996;88(14):956-965. (Pubitemid 26239383)
68. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol. 2005;23(9):1875-1884. (Pubitemid 46211365)
69. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 2008;98(3):523-528. (Pubitemid 351214533)
70. Shao RG, Cao CX, Shimizu T, et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 1997; 57(3):4029-35. (Pubitemid 27427693)
71. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16(2):376-383.
72. Dai Y, Yu C, Singh V, et al Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61(13):5106-5115. (Pubitemid 32681542)
73. Dai Y, Chen S, Shah R, et al. Disruption of Src function potentiates Chk1 inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood. 2011;117(6):1947-57.
74. Anderson VE, Walton MI, Eve PD, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011;71(2):463-472.
75. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004;64(24):9152-9159. (Pubitemid 39665530)
76. Nishida H, Tatewaki N, Nakajima Y, et al. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res. 2009;37(17):5678-5689.
77. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006; 66(10):5354-5362. (Pubitemid 43844961)
78. Dupré A, Boyer-Chatenet L, Sattler RM, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2008;4(2):119-125.
79. Chen X, Zhong S, Zhu X, et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 2008; 68(9):3169-3177.
80. Bapat A, Fishel ML, Kelley MR. Going APE as an approach to cancer therapeutics. Antioxid Redox Signal. 2009;11(3):651-668.
81. Wilson DM 3rd, Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci. 2010;67(21):3621-3631.
82. Kaina B, Margison GP, Christmann M. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci. 2010;67(21):3663-3668.
83. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 2007;67(15):7395-73405.
84. Chen S, Blank JL, Peters T, et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 2010;70(11):4318-4326.
85. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9(3): 1136-1144. (Pubitemid 36323723)
86. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010;116(22):4578-4587.
87. Gaymes TJ, Shall S, MacPherson LJ, et al, Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica. 2009;94(5):638-646.
88. Horton TM, Jenkins G, Pati D, et al. Poly(ADPribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009;8(8):2232-2242.
89. Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther. 2009;8(8):665-670.
90. Sibanda BL, Chirgadze DY, Blundell TL. Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats. Nature. 2010; 463(7277):118-121.
91. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111-1115. (Pubitemid 351317441)
92. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):688-695.
93. Bunting SF, Callén E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243-254.
94. Alexander BM, Sprott K, Farrow DA, et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res. 2010;16(23):5796-5804.
95. Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010;123(1):189-196.
96. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010;16(8):2344-2351.